AzTrials
AzTrials

Primary Progressive Multiple Sclerosis (PPMS)DEWNCT07831928

Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis.

A study testing Online wellness course and online exercise platform in people with Primary Progressive Multiple Sclerosis (PPMS) and Secondary Progressive Multiple Sclerosis (SPMS), run by University of Iowa at 1 site in United States.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to learn if an online wellness program can lower fatigue and improve mood and quality of life in people with progressive multiple sclerosis who are 45 to 70 years old and are experiencing significant fatigue disability. Read more about this study

Who is it for?
Ages 45 to 70 years
What is being tested?
Online wellness course and online exercise platform
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
118 participants
Where
1 siteUnited States
Study dates
15 Nov 2026to 15 Dec 2030
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Definitive diagnosis of Primary Progressive MS (PPMS) or Secondary Progressive MS (SPMS) based on the 2024 revised McDonald Criteria and confirmed by the treating neurologist who also approves participation.
  • Age 45 to 70 at the time of consent.
  • Must be fluent in both speaking and reading English.
  • Study participant must be able to read and comprehend informed consent document and speak with study staff about study document content. Study staff will use discretion in determining whether the study participant can clearly communicate with staff and comprehend the study material during the consent call or prior to the call.
  • Fatigue Severity Scale (FSS) score of greater than or equal to 4.
  • Ability to prepare, or availability of someone in the household to prepare, home-cooked meals.
Show all 9Show fewer
  • Willingness to commit to the study diet, 4-7-8 breathing technique, and a structured exercise program.
  • Access to high-speed internet with ownership of a device that can access the online programming and is capable of audio/video streaming.
  • Completion of online surveys at Month 0 (baseline), Month 3, \& Month 6.

Who cannot join

  • Confirmation of taking insulin or coumadin.
  • Documentation of relapse during the prior 4 weeks.
  • Use of corticosteroids during the prior 4 weeks.
  • Change or initiation of Disease Modifying Treatment (DMT) during the prior 4 weeks.
  • Treatment for cancer by radiation or chemotherapy within the prior 12 months.
  • Diagnosis of clinically significant heart, liver, or kidney disease, or history of oxalate kidney stones.
Show all 10Show fewer
  • Clinical diagnosis of psychiatric disease making study adherence difficult (e.g., schizophrenia) or an active eating disorder (anorexia, bulimia, binge eating, orthorexia).
  • Measurement of Body Mass Index (BMI) < 19.
  • Initiation of or change in medication to treat mood disorders in the prior 12 weeks.
  • Documentation of moderate or severe mental impairment (greater than or equal to 5 errors) as measured by the validated Short Portable Mental Health Questionnaire (SPMHQ).

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Mary Ehlinger, BS contact

319 3845002

CH-Studies@uiowa.edu

Whitney Schley, Schley contact

3193568555

whitney-schley@uiowa.edu

United States1 site
  • UI Health Care

    Iowa City, Iowa, 52242.

Other trials in United States

About this study

Official title: Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis: A Randomized Waitlist Controlled Trial (DEW Study)

The goal of this clinical trial is to learn if an online wellness program can lower fatigue and improve mood and quality of life in people with progressive multiple sclerosis who are 45 to 70 years old and are experiencing significant fatigue disability.

The main questions it aims to answer are:

Read more
  • Does the online wellness program lower fatigue after 3 months and further lower fatigue after 6 months?
  • Does the online wellness program improve anxiety, depression, and quality of life after 3 months and lead to additional improvements after 6 months? Researchers will compare participants who receive immediate access to the online wellness program with participants who continue their usual care and receive access to the program after the study ends.

Participants will:

  • Complete online surveys at the start of the study, at 3 months, and at 6 months. Each survey session takes less than 1 hour.
  • Complete a 7-day run-in period before randomization to confirm their interest and ability to complete study activities.
  • Be assigned by chance to either the online wellness program group or the wait-list control group.

Participants in the online wellness program group will:

  • Receive access to the "Creating Health" online course through the University of Iowa Canvas platform.
  • Work through five self-paced education modules over 6 months. Topics include nutrition, stress management, and physical activity.
  • Have access to monthly group coaching calls by Zoom.
  • Have access to an online exercise platform.
  • Have access to email and text support from the study team.

Participants in the wait-list control group will:

  • Continue their usual diet, lifestyle, and medical care during the 6-month study period.
  • Complete the same study surveys as the intervention group.
  • Receive full access to the online wellness program, online exercise platform and support materials after completing their final 6-month surveys.

At the end of the study, all participants will complete final surveys about their symptoms, quality of life, and their experience with the program. Active study participation ends after the 6-month assessments are completed.

Read the detailed description

Detailed Description Multiple sclerosis (MS) is a chronic neurodegenerative disease that affects nearly one million individuals in the United States. Progressive forms of the disease, including Primary Progressive Multiple Sclerosis (PPMS) and Secondary Progressive Multiple Sclerosis (SPMS), account for approximately 400,000 cases and are associated with substantial disability, fatigue, reduced quality of life, impaired mobility, mood disturbances, and cognitive challenges. Existing disease-modifying therapies have demonstrated effectiveness in reducing inflammatory disease activity but have limited impact on common disabling symptoms such as fatigue, anxiety, depression, and reduced health-related quality of life. Observational studies and preliminary intervention trials suggest that lifestyle factors, particularly diet quality, physical activity, and stress management practices, may improve symptoms and quality of life in people living with MS. However, high-quality randomized controlled trials evaluating integrated multimodal wellness interventions in individuals with progressive MS remain limited. This gap is particularly important because individuals with PPMS and SPMS often face barriers to in-person rehabilitation and wellness programs due to mobility limitations, transportation challenges, bowel and bladder dysfunction, and residence in rural communities. The purpose of the Evaluation of an Online, On demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis: A Randomized Waitlist controlled Trial (DEW Study) is to evaluate the effectiveness of a fully online, on-demand multimodal wellness intervention designed to reduce fatigue and improve quality of life among adults with progressive multiple sclerosis with significant fatigue disability. The intervention combines dietary education, structured exercise programming, stress management training, and behavioral support delivered through accessible virtual platforms. The DEW intervention consists of three primary components:1. Creating Health Online Wellness Course Delivered through the University of Iowa Canvas platform. Provides education regarding a modified Paleolithic dietary approach, with a Mediterranean dietary pathway available as an alternative. Emphasizes increased intake of nutrient-dense foods, including vegetables, and reduction of ultra-processed foods Includes practical resources related to meal planning, cooking skills, behavior change, and self-management strategies. 2. MS Gym Online Exercise Program A commercially available exercise platform specifically designed for individuals with multiple sclerosis. Provides mobility-level specific aerobic, resistance, balance, and functional movement exercises. Includes adaptations for seated and standing participation to accommodate varying levels of disability. 3. Stress Management Training. Participants are instructed in the 4-7-8 breathing technique, a structured breathing exercise intended to reduce stress and anxiety while supporting relaxation and sleep quality. Participants randomized to the intervention arm will also have access to monthly virtual group support sessions conducted via Zoom and facilitated by study personnel. These sessions utilize behavioral support and motivational interviewing principles to enhance adherence and self-efficacy. Participants may additionally communicate with the research team by email or text messaging for support throughout the intervention period. This study employs a randomized, waitlist-controlled design. Following informed consent, participants complete a 7-day run-in period designed to assess their ability to complete study procedures and baseline questionnaires. Participants who successfully complete baseline assessments will be randomized in a 1:1 ratio to either the intervention arm or a waitlist-control arm. Randomization is stratified by baseline fatigue severity. Participants assigned to the waitlist-control group will continue their usual diet, medical care, and lifestyle practices throughout the initial study period. They will receive general wellness information and monthly educational communications but will not have access to the wellness intervention during the primary comparison period. Following completion of the study assessments, waitlist participants will receive access to the Creating Health wellness course, the MS Gym exercise program, and a coaching session. Assessments are conducted electronically at baseline, Month 3, and Month 6 using validated patient-reported outcome measures. The primary outcome is change in fatigue severity, assessed using the Fatigue Severity Scale (FSS) at Month 3. Secondary outcomes include fatigue impact, health-related quality of life, mood, physical activity, dietary adherence, self-efficacy, social support, and participant acceptability of the intervention. Measures include the Modified Fatigue Impact Scale (MFIS), Multiple Sclerosis Quality of Life-54 (MSQOL-54), Hospital Anxiety and Depression Scale (HADS), Godin Leisure Time Exercise Questionnaire (GLTEQ), Physical Activity Vital Signs (PAVS), Mediterranean Diet Adherence Screener (MEDAS-14), Paleolithic Diet Adherence Screener (PDAS-12), Multiple Sclerosis Self-Efficacy Scale (MSSE), Multidimensional Scale of Perceived Social Support (MSPSS), Theoretical Framework of Acceptability questionnaire, and a Process Evaluation Questionnaire. The primary hypothesis is that participants receiving the DEW intervention will demonstrate greater improvements in fatigue at 3 months compared with participants receiving usual care. Secondary hypotheses are that intervention participants will experience improvements in quality of life, mood, physical activity, dietary adherence, self-efficacy, and perceived social support. Process evaluation measures will be used to identify barriers and facilitators to implementation and inform future dissemination of the intervention. By evaluating a scalable, fully virtual wellness program targeting fatigue and quality of life in progressive MS, this trial seeks to establish an accessible, non-pharmacologic approach that may help address important unmet needs among individuals living with progressive forms of multiple sclerosis.

Being tested
Online wellness course and online exercise platform, Usual Care Group
Keywords
nutrition, exercise, virtual intervention, stress management, fatigue
Medical subject headings
Multiple Sclerosis, Chronic Progressive, Motor Activity, Fatigue

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Online wellness course and online exercise platformBehavioural

    An online wellness course that teaches participants about behavior change, nutrition, exercise, stress management, and other wellness behaviors. Also includes access to an online exercise platform.

  • Usual Care GroupOther

    Participant will continue with their usual diet and wellness behaviors.

Study groups in NCT07831928
Study groupRoleWhat they receive
Intervention armExperimentalWellness online program and virtual exercise platform
Receives: Behavioral: Online wellness course and online exercise platform
Waitlist controlPlacebo comparatorContinues with usual care as directed by their neurologist
Receives: Other: Usual Care Group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Fatigue Severity Scale (FSS) Score

    The Fatigue Severity Scale (FSS) is a 9-item patient-reported questionnaire that measures the impact and severity of fatigue on daily functioning. Participants rate each item on a scale from 1 (strongly disagree) to 7 (strongly agree). The total score is calculated as the mean of the 9 items. Higher scores indicate greater fatigue severity. An FSS score ≥4 is commonly used to identify clinically significant fatigue in multiple sclerosis

    Measured: Baseline to 3 months

Secondary outcomes (13)
  1. Fatigue Severity Scale (FSS) Score

    The Fatigue Severity Scale (FSS) is a 9-item patient-reported questionnaire that measures the impact and severity of fatigue on daily functioning. Participants rate each item on a scale from 1 (strongly disagree) to 7 (strongly agree). The total score is calculated as the mean of the 9 items. Higher scores indicate greater fatigue severity. An FSS score ≥4 is commonly used to identify clinically significant fatigue in multiple sclerosis

    Measured: Baseline to 6 months

  2. Change in Modified Fatigue Impact Scale (MFIS) Score

    The MFIS evaluates the impact of fatigue on physical, cognitive, and psychosocial functioning during the previous 4 weeks.

    Score Range: 0 to 84

    Interpretation:

    Lower scores indicate less impact of fatigue. Higher scores indicate greater fatigue-related impairment. A decrease in score represents improvemen

    Measured: Baseline to month 3 and month 6.

  3. Change in Multiple Sclerosis Quality of Life-54 (MSQOL-54) Physical Health Composite Score

    The MSQOL-54 is a disease-specific quality-of-life measure that combines the SF-36 with MS-specific domains. The Physical Health Composite measures the impact of MS on physical functioning and health.

    Score Range: 0 to 100

    Interpretation:

    Higher scores indicate better physical health-related quality of life. An increase in score represents improvement.

    Measured: Baseline to month 3 and month 6

  4. Change in MSQOL-54 Mental Health Composite Score

    The Mental Health Composite of the MSQOL-54 assesses emotional well-being, cognitive health, social functioning, and mental health status.

    Score Range: 0 to 100

    Interpretation:

    Higher scores indicate better mental health-related quality of life. An increase in score represents improvement

    Measured: Baseline to month 3 and month 6

  5. Change in Hospital Anxiety and Depression Scale Anxiety Subscale (HADS-A)

    The HADS-A is a 7-item patient-reported measure assessing symptoms of anxiety. Score Range: 0 to 21

    Interpretation:

    Lower scores indicate fewer anxiety symptoms. Higher scores indicate greater anxiety. A decrease in score represents improvement.

    Severity Categories:

    0-7: Normal 8-10: Borderline abnormal 11-21: Clinically significant anxiety

    Measured: Baseline to month 3 and month 6

  6. Change in Hospital Anxiety and Depression Scale Depression Subscale (HADS-D) Score

    The HADS-D is a 7-item patient-reported measure assessing symptoms of depression.

    Score Range: 0 to 21

    Interpretation:

    Lower scores indicate fewer depressive symptoms. Higher scores indicate greater depression. A decrease in score represents improvement.

    Severity Categories:

    0-7: Normal 8-10: Borderline abnormal 11-21: Clinically significant depression

    Measured: Baseline to month 3 and month 6

  7. Change in Godin Leisure-Time Exercise Questionnaire (GLTEQ) Score

    The GLTEQ measures the frequency of mild, moderate, and strenuous leisure-time physical activity performed during a typical week.

    Score Range: 0 to approximately 119+ (no fixed upper limit)

    Interpretation:

    Higher scores indicate greater participation in physical activity. An increase in score represents improvement

    Measured: Baseline to month 3 and month 6

  8. Change in Physical Activity Vital Sign (PAVS) Weekly Minutes of Moderate-to-Vigorous Physical Activity

    The PAVS estimates the number of minutes per week spent engaging in moderate-to-vigorous physical activity.

    Score Range: 0 minutes to no fixed upper limit

    Interpretation:

    Higher values indicate greater physical activity participation. An increase in weekly minutes represents improvement

    Measured: Baseline to month 3 and month 6

  9. Change in Mediterranean Diet Adherence Screener (MEDAS-14) Score

    The MEDAS-14 assesses adherence to a Mediterranean dietary pattern using 14 dietary behavior questions.

    Score Range: 0 to 14

    Interpretation:

    Higher scores indicate greater adherence to a Mediterranean diet. An increase in score represents improvement.

    Measured: Baseline to month 3 and month 6

  10. Change in Paleolithic Diet Adherence Screener (PDAS-12) Score

    The PDAS-12 assesses adherence to a Paleolithic dietary pattern based on 12 dietary criteria.

    Score Range: 0 to 12

    Interpretation:

    Higher scores indicate greater adherence to a Paleolithic diet. An increase in score represents improvement

    Measured: Baseline to month 3 and month 6

  11. Change in Multiple Sclerosis Self-Efficacy Scale (MSSE) Score

    The MSSE assesses a participant's confidence in managing symptoms and daily challenges associated with multiple sclerosis.

    Score Range: 14 to 84

    Interpretation:

    Higher scores indicate greater self-efficacy. An increase in score represents improvement

    Measured: Baseline to month 3 and month 6

  12. Change in Multidimensional Scale of Perceived Social Support (MSPSS) Score

    The MSPSS is a 12-item questionnaire that measures perceived social support from family, friends, and significant others.

    Score Range: 12 to 84

    Interpretation:

    Higher scores indicate greater perceived social support. An increase in score represents improvement

    Measured: Baseline to month 3 and month 6

  13. Patient Determined Disease Steps (PDDS) Score

    The PDDS is a patient-reported measure of disability status in multiple sclerosis that correlates with the Expanded Disability Status Scale (EDSS).

    Score Range: 0 to 8

    Interpretation:

    0 = Normal 8 = Bedridden Lower scores indicate less disability. A decrease in score represents improvement

    Measured: Baseline to month 3 and month 6

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Sep 2026
  2. Study start15 Nov 2026 (estimated)
  3. Primary completion15 Nov 2029 (estimated)
  4. Study completion15 Dec 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
Wait list control. The control group receives access to the online wellness course and the virtual exercise platform at the conclusion of the study.
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
118 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07831928
Sponsor's protocol ID
202602218
Other IDs
202602218
Acronym
DEW
Status last verified
Sep 2026
First submitted
15 Sep 2026
Last updated
28 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: After publication of results, relevant IPD published data will be shared for scientists who are conducting meta-analyses with a published protocol for PROSPERO registered meta-analysis.

Publications

  • Titcomb TJ, Sherwood M, Ehlinger M, Saxby SM, Shemirani F, Eyck PT, Wahls TL, Snetselaar LG. Evaluation of a web-based program for the adoption of wellness behaviors to self-manage fatigue and improve quality of life among people with multiple sclerosis: A randomized waitlist-control trial. Mult Scler Relat Disord. 2023 Sep;77:104858. doi: 10.1016/j.msard.2023.104858. Epub 2023 Jun 27.

    PubMed 37399671
  • Elliott-Wherry AN, Lee JE, Pearlman AM, Wahls TL. The Wahls Behavior Change Model for Complex Chronic Diseases: A Clinician's Guide. Degener Neurol Neuromuscul Dis. 2022 Sep 9;12:111-125. doi: 10.2147/DNND.S370173. eCollection 2022.

    PubMed 36110247
  • Lee JE, Titcomb TJ, Bisht B, Rubenstein LM, Louison R, Wahls TL. A Modified MCT-Based Ketogenic Diet Increases Plasma beta-Hydroxybutyrate but Has Less Effect on Fatigue and Quality of Life in People with Multiple Sclerosis Compared to a Modified Paleolithic Diet: A Waitlist-Controlled, Randomized Pilot Study. J Am Coll Nutr. 2021 Jan;40(1):13-25. doi: 10.1080/07315724.2020.1734988. Epub 2020 Mar 26.

    PubMed 32213121
  • Bisht B, Darling WG, White EC, White KA, Shivapour ET, Zimmerman MB, Wahls TL. Effects of a multimodal intervention on gait and balance of subjects with progressive multiple sclerosis: a prospective longitudinal pilot study. Degener Neurol Neuromuscul Dis. 2017 Jun 26;7:79-93. doi: 10.2147/DNND.S128872. eCollection 2017.

    PubMed 30050380
  • Lee JE, Bisht B, Hall MJ, Rubenstein LM, Louison R, Klein DT, Wahls TL. A Multimodal, Nonpharmacologic Intervention Improves Mood and Cognitive Function in People with Multiple Sclerosis. J Am Coll Nutr. 2017 Mar-Apr;36(3):150-168. doi: 10.1080/07315724.2016.1255160. Epub 2017 Apr 10.

    PubMed 28394724
  • Bisht B, Darling WG, Grossmann RE, Shivapour ET, Lutgendorf SK, Snetselaar LG, Hall MJ, Zimmerman MB, Wahls TL. A multimodal intervention for patients with secondary progressive multiple sclerosis: feasibility and effect on fatigue. J Altern Complement Med. 2014 May;20(5):347-55. doi: 10.1089/acm.2013.0188. Epub 2014 Jan 29.

    PubMed 24476345
  • Wahls TL, Reese D, Kaplan D, Darling WG. Rehabilitation with neuromuscular electrical stimulation leads to functional gains in ambulation in patients with secondary progressive and primary progressive multiple sclerosis: a case series report. J Altern Complement Med. 2010 Dec;16(12):1343-9. doi: 10.1089/acm.2010.0080.

    PubMed 21138391
  • Reese D, Shivapour ET, Wahls TL, Dudley-Javoroski SD, Shields R. Neuromuscular electrical stimulation and dietary interventions to reduce oxidative stress in a secondary progressive multiple sclerosis patient leads to marked gains in function: a case report. Cases J. 2009 Aug 10;2:7601. doi: 10.4076/1757-1626-2-7601.

    PubMed 19918474

Questions about this trial

What is this clinical trial studying?

A study testing Online wellness course and online exercise platform in people with Primary Progressive Multiple Sclerosis (PPMS) and Secondary Progressive Multiple Sclerosis (SPMS), run by University of Iowa at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 28 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Mary Ehlinger, BS (319 3845002, CH-Studies@uiowa.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Fatigue Severity Scale (FSS) Score (time frame: Baseline to 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07831928, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in